Assessment for ease of use and preference of a new prefilled insulin pen (FlexTouch Degludec U100/U200) versus the SoloSTAR insulin pen by patients with diabetes and healthcare professionals.

Science

First published in Expert Opinion on Drug Delivery on 2014 Sep.
Expert Opin Drug Deliv. 2014 Sep;11(9):1381-9. doi: 10.1517/17425247.2014.927438. Epub 2014 Jun 12.

Authors: Pfützner A, Forst T, Niemeyer M, Bailey T

Download full article as Pdf file:

Pdf File

REACHING OUT IS EASY AND FAST – LET’S TALK

Prof. Dr. Thomas Forst

Chairman of the Executive Board

LET’S TALK SCIENCE

+49 621 150 45 – 0

Martin Mulder

Senior Vice President Corporate & Business Development

LET’S TALK BUSINESS

+49 621 150 45 – 0

Assessment for ease of use and preference of a new prefilled insulin pen (FlexTouch Degludec U100/U200) versus the SoloSTAR insulin pen by patients with diabetes and healthcare professionals.

Read more

REACHING OUT IS EASY AND FAST – LET’S TALK

You May Also Like

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies.

(Bersacapavir) In Participants With Moderate Hepatic Impairment.